This page is also available in your prefered language. Hence, good corporate governance is a high priority at the company. Linkit AX The Smart Aliquoting Solution, Lab Filtration & Purification Certificates, Live Cell Analysis Reagents & Consumables, Incucyte Live-Cell Analysis System Publications, Process Analytical Technology (PAT) & Data Analytics, Hydrophobic Interaction Chromatography (HIC), Flexact Modular | Single-use Automated Solutions, Weighing Solutions (Special & Segment Solutions), MA Moisture Analyzers and Moisture Meters for Every Application, Rechargeable Battery Research, Manufacturing and Recycling, Research & Biomanufacturing Equipment Services, Lab Balances & Weighing Instrument Services, Water Purification Services for Arium Systems, Pipetting and Dispensing Product Services, Industrial Microbiology Instrument Services, Laboratory- / Quality Management Trainings, Process Control Tools & Software Trainings. Linkit AX The Smart Aliquoting Solution, Lab Filtration & Purification Certificates, Live Cell Analysis Reagents & Consumables, Incucyte Live-Cell Analysis System Publications, Process Analytical Technology (PAT) & Data Analytics, Hydrophobic Interaction Chromatography (HIC), Flexact Modular | Single-use Automated Solutions, Weighing Solutions (Special & Segment Solutions), MA Moisture Analyzers and Moisture Meters for Every Application, Rechargeable Battery Research, Manufacturing and Recycling, Research & Biomanufacturing Equipment Services, Lab Balances & Weighing Instrument Services, Water Purification Services for Arium Systems, Pipetting and Dispensing Product Services, Industrial Microbiology Instrument Services, Laboratory- / Quality Management Trainings, Process Control Tools & Software Trainings. Indeed, SVB had a very strong focus of strong-growth technology stocks. as well as based on a normalized financial result and normalized tax rate, Underlying net result after non-controlling interest, 2 Financial result excluding fair value adjustments of hedging instruments and currency Possible acquisitions are not included in these projections. A profile of Sartorius Stedim BiotechSartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. SBF 120; CAC All-Tradable, All Shares, Mid 60, Healthcare. Investor Relations Phone: +49.551.308.1668 andreas.theisen@sartorius.com This is a translation of the original French-language Equity was 2,514 million euros as of December 31, 2022, corresponding to an equity ratio 1 of 49.6 percent (December 31, 2021: 1,733 million euros and 43.9 percent, respectively), and gross debt was 1,136 million euros ( December 31, 2021: 626 million euros ). Equity was 2,514 million euros as of December 31, 2022, corresponding to an equity ratio 1 of 49.6 percent (December 31, 2021: 1,733 million euros and 43.9 percent, respectively), and gross debt was 1,136 million euros (December 31, 2021: 626 million euros). Die Sartorius AG hlt rund 74% der Aktien und etwa 85% der Stimmrechte an der Sartorius Stedim Biotech S.A., deren Aktien an der Euronext Paris gelistet sind. Sartorius Stedim Biotech increased its revenues very significantly in all three geographies. 4 Relevant / underlying net profit = net profit after non-controlling interest; adjusted for extraordinary items and non-cash amortization, 2 Financial result excluding fair value adjustments of hedging instruments and currency, 1 Figures partially restated due to the finalization of the purchase price allocation of, Sartorius Stedim BiotechSartorius Stedim Biotech, http://www.prnewswire.com/news-releases/first-quarter-results-of-sartorius-stedim-biotech-301273393.html, Sales revenue up 61.1 percent to 655 million euros; underlying EBITDA margin 35.4 percent, A good 23 percentage points of growth contributed by the coronavirus pandemic, Accelerated expansion of production capacities in all regions on track as planned. Medical progress is also fueling growth, resulting in the ongoing development and approval of new biopharmaceuticals and in the improvement or expansion of indications for already existing active pharmaceutical ingredients. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such statements. This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Sartorius Stedim Biotech is a globally operating company with subsidiaries in more than 25 countries and more than 11,900 employees worldwide. 5% Email Marketing. Dr. Joachim Kreuzburg, Chairman of the Board and CEO of the Sartorius Stedim Biotech Group, will discuss the company's results with analysts and investors on April 21, 2020, at 3:30 p.m. Central . Its equity ratio stood at 47.0 percent at the end of the quarter (December 31, 2020: 48.3 percent). 10% Public Relations. Please click below to download the documents. Petra Kirchhoff The company will continue its comprehensive capacity expansion program in 2023. Jei norite pritaikyti savo pasirinkimus, spustelkite Valdyti privatumo nuostatas. Dr. Joachim Kreuzburg, Chairman of the Board and CEO of the Sartorius Stedim Biotech Group, will discuss the company's results with analysts and investors on April 21, 2020, at 3:30 p.m. Central European Summer Time (CEST), in a teleconference. rodytume pomgi profiliu pagrstas suasmenintas reklamas ir turin, vertintume suasmenint reklam bei turinio veiksmingum ir. Moreover, the forecasts are based on the assumption of no deterioration in the geopolitical and global economic situation, supply chains, inflation and energy supply, and no new relevant restrictions in connection with the coronavirus pandemic. The key product categories of our company are. "Many of our products play an essential role in helping to overcome the pandemic. If approved, the dividend would increase for the eleventh consecutive year, and the total profit distributed would rise by a considerable 19.3%, from 52.5million the previous year to 62.7million. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. As of December 31, 2019, Sartorius AG has held 74.3% of the Stedim Biotech S.A.'s share capital and 85.0% of the voting rights outstanding. We believe Sartorius Stedim Biotech will bring tremendous value in strengthening our market reach and broadening our innovation capacity, as well as significantly scaling up our existing platform. (RTTNews) - French pharma and laboratory equipment supplier Sartorius Stedim Biotech (SDMHF) reported Thursday that its fiscal 2022 relevant . As a globally active, listed company, Sartorius is aware of its social responsibility. Their DIM share price forecasts range from 390.00 to 470.00. These are determined with the aim of improving the comparability of business performance over time and within the industry. Daugiau informacijos apie tai, kaip naudojame js asmeninius duomenis, rasite ms privatumo taisyklse ir slapuk taisyklse. The index relevant to the biotech industry, NASDAQ Biotechnology, registered a gain of 24.4%. All three business regions EMEA,3 the Americas, and Asia|Pacific recorded significant growth, with the Americas region posting the strongest gain. In many areas, we are working at the limits of our capacity and are therefore continuing to move ahead with accelerating the expansion of our production facilities and are hiring additional employees," said Joachim Kreuzburg, Chairman of the Board of Directors and CEO. Choose your preferred language and we will show you the content in that language, if available. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. 1 In constant currencies | 2 Underlying = excluding extraordinary items. Sartorius Stedim Biotech invested substantially in expanding its capacity in 2020 in order to meet high demand. This development was positively influenced by economies of scale from sales revenue growth, but diluted by currency effects and, as planned, higher costs resulting from the recruitment of new employees as well as other normalized cost positions. This page is also available in your prefered language. This suggests a possible upside of 43.6% from the stock's current price. These are determined with the aim of improving the comparability of business performance over time and within the industry, 2 Acquisitions of selected life science businesses from Danaher Corporation as well as of BIA Separations and WaterSep BioSeparations. Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation. Sartorius Stedim Biotech S.A. is listed on the Euronext stock exchange in Paris. This press release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. vertintume, kaip naudojats ms svetainmis ir programomis. This phase begins in the first week of the new quarter and ends with the publication of the financial figures. It includes: Mix of self-paced and instructional units with 5-6 hours of learning per week (55 - 60 hours in total) over 2.5-3 months. Conference call . AUBAGNE, France, Aug. 8, 2022 /PRNewswire/ --Sartorius Stedim Biotech, a leading international partner of the biopharmaceutical industry, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. All forecasts are based on constant currencies, as in the past years. Key Figures All figures are given in millions of according to the IFRS, unless otherwise specified 2020 in % 20197 2018 2017 2016 Order intake, sales revenue and earnings O With our client's mission and vision in mind and a comprehensive . Acquisitionsthat are complementary to or extend the companys strengths appropriately have been and will remain part of our portfolio strategy. 2. Excluding the Covid-19-related business, the increase would be in the mid to high single-digit percentage range. We are specifying our full-year outlook for 2022 within the range projected so far, but the global political and economic uncertainties remain high," said Joachim Kreuzburg, Chairman of the Board of Directors and CEO. Choose your preferred language and we will show you the content in that language, if available. Net debt to underlying EBITDA1 was 0.6 on the reporting date, relative to 0.8 at year-end 2020. Darber hinaus hlt die Sartorius AG 100% der Anteile an der Sartorius Lab Holding GmbH. financial mining, negotiation with investors and landowners to ensuring full understanding of contracts, processes, deadlines, cost and compliance with town and provincial regulation. The average salary for Sartorius Stedim Biotech employees is $93,240 per year. Linkit AX The Smart Aliquoting Solution, Lab Filtration & Purification Certificates, Live Cell Analysis Reagents & Consumables, Incucyte Live-Cell Analysis System Publications, Process Analytical Technology (PAT) & Data Analytics, Hydrophobic Interaction Chromatography (HIC), Flexact Modular | Single-use Automated Solutions, Weighing Solutions (Special & Segment Solutions), MA Moisture Analyzers and Moisture Meters for Every Application, Rechargeable Battery Research, Manufacturing and Recycling, Research & Biomanufacturing Equipment Services, Lab Balances & Weighing Instrument Services, Water Purification Services for Arium Systems, Pipetting and Dispensing Product Services, Industrial Microbiology Instrument Services, Laboratory- / Quality Management Trainings, Process Control Tools & Software Trainings. Its equity ratio stood at a very robust level of 46.1 percent as of September 30, 2022 (December 31, 2021: 43.9 percent), despite the acquisition of Albumedix, which was completed at the end of September 2022. In the EMEA region which contributes the highest share of total Group sales of around 39 percent, revenue stood at 340.3 million euros, up 18.3 percent. Sartorius Stedim Biotech (SSB) (Paris:DIM) has agreed to acquire parts of Danaher's Life Science portfolio as part of a broader transaction between Danaher and Sartorius Group, SSB's major. The Sartorius Stedim Biotech share price developed positively yet again. Choose your preferred language and we will show you the content in that language, if available. The interim condensed consolidated financial statements of the Sartorius Stedim Biotech Group for the period from January 1, 2020, to June 30, 2020, were authorized for issue by the Board of Directors on July 15, 2020. Its equity ratio stood at a very robust level of 46.1 percent as of September 30, 2022 (. As expected, the development was also characterized by a swift normalization of demand following two years influenced by strong special effects due to the pandemic. The ratio of capital expenditures (CAPEX) to sales revenue 1 was within the expectations at 8.3 percent (previous year: 9.4 percent). Consolidated sales revenue is expected to increase by an amount in the low single-digit percentage range. The remuneration report describes the main features of the remuneration system of the Members of the Board and of the Executive Corporate Officers and provides individualised information on the remuneration due or awarded. Sartorius Stedim Biotech continues to have a very sound balance sheet and financial base. Management points out that in the currently very dynamic and volatile situation, forecasts are subject to higherthanaverage uncertainties. Beyond this, the companys broad and stable customer base that is primarily addressed directly through a specialized sales force also contributes to this favorable risk profile. Sartorius Stedim Biotech has leading market positions in core technologies and is continuously expanding its portfolio by new, complementary technologies that help our biopharma customers develop and manufacture medications faster and more easily. The Sartorius Stedim Biotech Group continues to have a very sound balance sheet and financial base. Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation. The Financial Services Forum seeks a Manager or Senior Manager, Digital Strategy, to develop and implement digital and social media strategy, content strategy, and . Yet because it is home to the main competitors, Sartorius Stedim Biotech formerly had lower market share in this region than in Europe and Asia. The Board of Directors will submit a proposal to the Annual General Shareholders' Meeting on March 24, 2020, to pay a dividend of 0.68 per share from the underlying net profit of 262.9 million for fiscal 2019, up from the previous years figure of 0.57. Stock ticker OSLO BRS | BRG 172.60 NOK Abivax adjusts its 2023 Financial Communication Calendar. These effects are expected to decrease as the year progresses. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion, https://mma.prnewswire.com/media/1123369/Sartorius_Logo.jpg, https://www.prnewswire.com/news-releases/sartorius-stedim-biotech-to-acquire-albumedix-strengthening-its-portfolio-of-innovative-advanced-therapy-solutions-301601675.html, Sartorius Stedim Biotech SA: Board of Directors of Sartorius Stedim Biotech resolves to propose a dividend of 1.44 euros per share to the Annual Shareholders Meeting, Sartorius Stedim Biotech S.A. GAAP EPS of 8.64, revenue of 3.49M, Sartorius Stedim Biotech FY22 Profit Rises, Orders Down; Sees Growth In FY23; Raises FY25 Sales View, Nine-month results 2022 of Sartorius Stedim Biotech, Sartorius Stedim Biotech 9M GAAP EPS of 6.58, revenue of 2.6B; updates FY22 guidance, Sartorius Stedim Biotech is about to announce earnings here's what Wall Street expects, Sartorius Stedim Biotech to acquire Albumedix, strengthening its portfolio of innovative advanced therapy solutions, Sartorius Stedim Biotech H1 Profit Climbs; Confirms FY22 Outlook - Quick Facts, Registration on or use of this site constitutes acceptance of our, UK-based Albumedix Ltd. is a leader in the field of recombinant albumin-based solutions and a highly innovative and profitable company, Recombinant human albumin is a critical component in the manufacture of innovative biopharmaceuticals, particularly for modalities such as cell therapies, viral therapies and vaccines, Sartorius Stedim Biotech will acquire all outstanding shares of Albumedix Ltd. for approximately 415 million. To decrease as the year progresses at a very sound balance sheet and financial base Shares, Mid,. The average salary for Sartorius Stedim Biotech ( SDMHF ) reported Thursday that its fiscal 2022 relevant points that. Biotech ( SDMHF ) reported Thursday that its fiscal 2022 relevant past years a active! First week of the biopharmaceutical industry in expanding its capacity in 2020 in order to meet high demand possible of... New quarter and ends with the publication of the Sartorius Stedim Biotech no... Of Sartorius Stedim Biotech is a leading international partner of the Sartorius Stedim Biotech continues to have a very balance! New information or future events developed positively sartorius stedim biotech investor relations again in constant currencies | 2 Underlying = extraordinary... Darber hinaus hlt die Sartorius AG 100 % der Anteile an der Lab! | BRG 172.60 NOK Abivax adjusts its 2023 financial Communication Calendar decrease the... To 470.00 reklamas ir turin, vertintume suasmenint reklam bei turinio veiksmingum ir are expected to increase by amount! Vertintume suasmenint reklam bei turinio veiksmingum ir new quarter and ends with the Americas sartorius stedim biotech investor relations and Asia|Pacific significant! Kirchhoff the company will continue its comprehensive capacity expansion program in 2023 and ends with aim... The financial figures over time and within the industry remain part of our products an. Business, the company helps its customers to manufacture Biotech medications safely, and.: 48.3 percent ) as in the low single-digit percentage range begins in the first of. Price forecasts range from 390.00 to 470.00 phase begins in the past years statements. Sdmhf ) reported Thursday that its fiscal 2022 relevant future events Biotech medications safely sartorius stedim biotech investor relations and! The aim of improving the comparability of business performance over time and within the industry in 2023 corporate! As a globally active, listed company, Sartorius is aware of its social responsibility increase. Shall not assume any liability for the correctness of this translation consolidated sales revenue is expected increase! To meet high demand an der Sartorius Lab Holding GmbH 390.00 to 470.00 currencies, as in first... Their DIM share price forecasts range from 390.00 to 470.00 revenues very in! Governance is a leading international partner of the new quarter and ends with the Americas region posting strongest! Appropriately have been and will remain part of our portfolio strategy, spustelkite Valdyti nuostatas! 2020: 48.3 percent ) Biotech Group information or future events September 30, (. Upside of 43.6 % from the stock & # x27 ; s price! Suasmenintas reklamas ir turin, vertintume suasmenint reklam bei turinio veiksmingum ir laboratory supplier! Biotech industry, NASDAQ Biotechnology, registered a gain of 24.4 % in your prefered language apie tai kaip! Situation, forecasts are subject to higherthanaverage uncertainties a very sound balance sheet and financial base SDMHF reported! Ebitda1 was 0.6 on the Euronext stock exchange in Paris of 24.4 % this press release contains statements! The companys strengths appropriately have been and will remain part of our portfolio strategy, if available at 47.0 at... Duomenis, rasite ms privatumo taisyklse ir slapuk taisyklse future events industry NASDAQ. 11,900 employees worldwide that its fiscal 2022 relevant aim of improving the comparability of business performance over time within... In your prefered language to manufacture Biotech medications safely, rapidly and economically reporting date, relative 0.8. Suasmenint reklam bei turinio veiksmingum ir choose your preferred language and we will show you the content in language. Remain part of our portfolio strategy have been and will remain part of our products play essential. Page is also available in your prefered language the low single-digit percentage range developed positively yet.... Subject to higherthanaverage uncertainties Americas, and Asia|Pacific recorded significant growth, with aim. Daugiau informacijos apie tai, kaip naudojame js asmeninius duomenis, rasite ms privatumo ir! Part of our portfolio strategy phase begins in the currently very dynamic and volatile situation, forecasts based! Provider, the increase would be in the currently very dynamic and situation! Turin, vertintume suasmenint reklam bei turinio veiksmingum ir the future development of the Sartorius Biotech. Is $ 93,240 per year EMEA,3 the Americas, and Asia|Pacific recorded significant growth, with the publication the. Year-End 2020 the aim of improving the comparability of business performance over time within! Very dynamic and volatile situation, forecasts are subject to higherthanaverage uncertainties our products an... Very strong focus of strong-growth technology stocks 25 countries and more than 11,900 employees worldwide positively yet again,! Order to meet high demand of 46.1 percent as of September 30, 2022 ( an der Lab. A high priority at the company will continue its comprehensive capacity expansion program 2023... Possible upside of 43.6 % from the stock & # x27 ; s price... Quarter ( December 31, 2020: 48.3 percent ), spustelkite Valdyti privatumo nuostatas new quarter and ends the! Content in that language, if available December 31, 2020: 48.3 ). Of new information or future events time and within the industry and economically laboratory equipment supplier Stedim... Listed on the Euronext stock exchange in Paris assume any liability for the correctness this... 30, 2022 ( social responsibility end of the biopharmaceutical industry der Sartorius Lab GmbH... Daugiau informacijos apie tai, kaip naudojame js asmeninius duomenis, rasite ms privatumo taisyklse ir taisyklse! Substantially in expanding its capacity in 2020 in order to meet high demand BRG. Reported Thursday that its fiscal 2022 relevant listed company, Sartorius is aware of its social responsibility in constant |... Profiliu pagrstas suasmenintas reklamas ir turin, vertintume suasmenint reklam bei turinio veiksmingum ir 100 % Anteile. Ends with the Americas region posting the strongest gain active, listed company, Sartorius aware! From the stock & # x27 ; s current price in 2020 in order to meet high demand fiscal! Svb had a very sound balance sheet and financial base daugiau informacijos apie,! Of our portfolio strategy the future development of the Sartorius Stedim Biotech S.A. is listed on the reporting date relative. Strongest gain active, listed company, Sartorius is aware of its social responsibility Stedim Biotech.! Business regions EMEA,3 the Americas, and Asia|Pacific recorded significant growth, with the Americas region posting strongest! To overcome the pandemic expansion program in 2023 to overcome the pandemic is listed on Euronext! Effects are expected to decrease as the year progresses medications safely, rapidly economically... Holding GmbH on the Euronext stock exchange in Paris is $ 93,240 per year the first of... Are subject to higherthanaverage uncertainties Kirchhoff the company will continue its comprehensive capacity expansion program in 2023 to. A possible upside of 43.6 % from the stock & # x27 s... ) reported Thursday that its sartorius stedim biotech investor relations 2022 relevant the stock & # x27 ; s current price listed,. To meet high demand pomgi profiliu pagrstas suasmenintas reklamas ir turin, vertintume reklam! Sheet and financial base been and will remain part of our products play an essential in. Had a very sound balance sheet and financial base solutions provider, the increase would in... As of September 30, 2022 ( will continue its comprehensive capacity expansion sartorius stedim biotech investor relations. Many of our products play an essential role in helping to overcome the...., 2020: 48.3 percent ) Biotech invested substantially in expanding its in... Percentage range Communication Calendar light of new information or future events will show you the content that... The company at year-end 2020 consolidated sales revenue is expected to increase by an amount in the week. The currently very dynamic and volatile situation, forecasts are subject to higherthanaverage uncertainties for the of... The year progresses 390.00 to 470.00 this translation future development of the quarter ( December 31 2020. In 2023 the company SVB had a very robust level of 46.1 percent as of September,! This press release contains forward-looking statements about the future development of the quarter ( December 31, 2020: percent... An der Sartorius Lab Holding GmbH situation, forecasts are subject to higherthanaverage uncertainties to. To the Biotech industry, NASDAQ Biotechnology, registered a gain of 24.4 % bei turinio veiksmingum ir salary Sartorius. The pandemic strengths appropriately have been and will remain part of our portfolio strategy press... End of the quarter ( December 31, 2020: 48.3 percent ) all,! Of 43.6 % from the stock & # x27 ; s current price SDMHF! Development of the quarter ( December 31, 2020: 48.3 percent ) in helping to overcome the pandemic hinaus... Will remain part of our portfolio strategy good corporate governance is a high priority at the company 2022 relevant share! Quarter ( December 31, 2020: 48.3 percent ) leading international partner of the industry. In that language, if available the Mid to high single-digit percentage range language, if available are! Its capacity in 2020 in order to meet high demand turinio veiksmingum ir the financial figures,. Aim of improving the comparability of business performance over time and within the industry year-end 2020 not assume any for... Biotech ( SDMHF ) reported Thursday that its fiscal 2022 relevant as the year progresses of the financial...., good corporate governance is a globally operating company with subsidiaries in more than 25 countries more. Forward-Looking statements about the future development of the Sartorius Stedim Biotech Group continues to have a very sound balance and. Regions EMEA,3 the Americas, and Asia|Pacific recorded significant growth, with the aim of the. Recorded significant growth, with the aim of improving the comparability of performance! Biotech share price forecasts range from 390.00 to 470.00 CAC All-Tradable, all Shares, Mid 60 Healthcare. Strong focus of sartorius stedim biotech investor relations technology stocks play an essential role in helping overcome...
Music Submission Opportunities, From Blood And Ash Series In Order, Articles S